Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020002 · ClinicalTrials.gov registry record
Extracellular RNA Biomarkers of Myotonic Dystrophy
A clinical trial of Myotonic Dystrophy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 215
- Enrollment target
- 3
- Study locations
NCT05020002 is a study of Myotonic Dystrophy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 215 participants, below the 832-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05020002, a study of Myotonic Dystrophy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 215 participants
- Enrollment target
- 3
- Study locations
Study Summary
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample.
Conditions Studied
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05020002
The ClinicalTrials.gov registry entry for NCT05020002 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 832-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (74% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myotonic Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT05020002 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT05020002 about?
NCT05020002 is a clinical study titled "Extracellular RNA Biomarkers of Myotonic Dystrophy". Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is t...
What is the current status of trial NCT05020002?
This trial is currently recruiting. The enrollment target is 215 participants. The study started on 2020-12-08. Estimated completion is 2027-12.
What conditions does trial NCT05020002 study?
This clinical trial studies the following conditions: Myotonic Dystrophy.
Who is sponsoring clinical trial NCT05020002?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020002 being conducted?
This trial has 3 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
RECRUITING · Phase 1
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
RECRUITING
-
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
RECRUITING
-
Myotonic Dystrophy Family Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.